In contrast, co-administration of SFV-VEGFR-2 and SFV-IL-4 particles enhanced VEGFR-2-specific antibody titers and extended survival of mice after tumor challenges compared to immunization with only SFV-VEGFR-2 particles. This evidence concerns the gene KDR and neoplasm.